Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 68% of the company
A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...
The Pharma Letter1d
New data could tee up broader label for Talzenna combination
US pharma giant Pfizer has announced positive results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral ...
Why Pfizer (PFE) Is Declining?
We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...
The Pharma Letter1d
New FDA approval for Pfizer’s Adcetris
The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
Pfizer director Ronald E. Blaylock acquires $499,072 in stock
Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...
Armed robbery in Revesby1d
FDA OKs Pfizer's ADCETRIS Combo for Relapsed Lymphoma
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...
Investing1d
Pfizer Inc DRC (PFE)
2-adapted COVID-19 Vaccine Pfizer Inc. (NYSE:PFE, “Pfizer”) and BioNTech SE (NASDAQ:BNTX) (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA ...